Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Blood

Volumn 119, Issue 20, 2012, Pages 4614-4618

  Eghtedar, Alireza ^a   Verstovsek, Srdan ^a   Estrov, Zeev ^a   Burger, Jan ^a   Cortes, Jorge ^a   Bivins, Carol ^a   Faderl, Stefan ^a   Ferrajoli, Alessandra ^a   Borthakur, Gautam ^a   George, Solly ^a   Scherle, Peggy A ^b   Newton, Robert C ^b   Kantarjian, Hagop M ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CYTOPENIA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYELOPROLIFERATIVE NEOPLASM; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLEEN SIZE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84861216420     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-400051     Document Type: Article

References (26)

1. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006;6(8):671-679. (Pubitemid 44875961)
2. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996;272(5262): 719-722.
3. Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 1996; 15(10):2425-2433. (Pubitemid 26151182)
4. Chaturvedi P, Reddy MV, Reddy EP. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene. 1998; 16(13):1749-1758. (Pubitemid 28175056)
5. O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998;17(4):1006-1018. (Pubitemid 28077655)
6. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000;19(21):2496-2504. (Pubitemid 30339205)
7. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma. 2008;49(3):388-397. (Pubitemid 351298324)
8. Spiekermann K, Biethahn S, Wilde S, HiddemannW, Alves F. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol. 2001;67(2):63-71. (Pubitemid 33010380)
9. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17(18):5321-5333. (Pubitemid 28427047)
10. Schwaller J, Parganas E, Wang D, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell. 2000; 6(3):693-704.
11. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281. (Pubitemid 43801351)
12. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006; 108(10):3548-3555.
13. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-2900.
14. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
15. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2006;103(17):6688-6693.
16. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468-6472. (Pubitemid 44085597)
17. Wang Y, Cai D, Brendel C, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/ STAT-5 pathway activation. Blood. 2007;109(5): 2147-2155. (Pubitemid 46348217)
18. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 2010;13(6): 394-403.
19. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649. (Pubitemid 46594039)
21. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-425. (Pubitemid 44061337)
22. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977. (Pubitemid 40170863)
23. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008;32(4): 587-591. (Pubitemid 351248959)
24. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/ polycythemia vera myelofibrosis. Leukemia. 2008;22(5):965-970. (Pubitemid 351689878)
25. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116(19):3735-3742.
26. Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010;34(9):1246-1249.